Summary of ImmuCell Corporation Q2 2026 Earnings Call

1Key Financial Results and Metrics

Product Sales: Q2 2026 product sales totaled $7.2 million, an 11.5% increase year-over-year. For the first half of 2026, sales reached $17.5 million, up 20.9% compared to the same period in 2025.

Domestic vs. International Sales: Domestic sales grew 27.7% to $6.2 million, while international sales declined 38.9% to approximately $1 million, primarily due to a backorder situation in Canada.

Gross Margin: Gross margin was 33.9% in Q2 2026, down from 43.7% in Q2 2025, attributed to cost shifts and lower manufacturing output.

Net Income: Net income for Q2 was $1.8 million ($0.20 per share), compared to $500,000 ($0.06 per share) in Q2 2025. For the first half, net income was $3.8 million, up from $1.9 million in 2025.

Adjusted EBITDA: Q2 adjusted EBITDA was $2.7 million, compared to $1.4 million in Q2 2025.

2Strategic Updates and Business Highlights

Focus on Calf Scours Market: ImmuCell has shifted its strategic focus to the calf scours market, particularly enhancing its First Defense product line.

Capacity Expansion: The company announced a $3.5 million investment in freeze-drying capacity and plans to invest $4.5 million in liquids processing capacity, aiming to triple current manufacturing capacity by the end of 2027.

Market Share Growth: First Defense's market share increased from 15% to 19% in the U.S., with spending share rising from 29% to 38%.

Sales Team Expansion: The company has expanded its sales team, resulting in strong customer acquisition and increased distributor volume growth.

3Forward Guidance and Outlook

ImmuCell expects to complete its capacity expansion initiatives by the end of 2027, which will enhance product availability and reduce costs.

The company remains focused on improving yields and managing contamination risks while meeting growing customer demand.

4Bad News, Challenges, or Points of Concern

Declining International Sales: The significant drop in international sales, particularly in Canada, poses a concern for overall growth.

Gross Margin Pressures: The decline in gross margin due to cost shifts and lower manufacturing output is a notable challenge, especially as the company seeks to improve profitability.

Manufacturing Capacity Constraints: Historically, growth has been constrained by manufacturing capacity, and while expansion plans are underway, execution risks remain.

5Notable Q&A Insights

Re-Tain Product Development: Ongoing studies with Michigan State University regarding the Re-Tain product are expected to conclude by September/October 2026, with results to be shared with investors.

Distribution Dynamics: The company clarified that changes in customer distribution patterns are largely due to timing and geographic factors rather than strategic shifts.

Seasonality in Sales: There is a noted seasonality in sales between dairy and beef markets, with dairy sales being more stable year-round compared to beef, which peaks during calving seasons. Overall, ImmuCell demonstrated strong growth in product sales and net income, while also outlining significant strategic initiatives aimed at expanding capacity and market share. However, challenges related to international sales and gross margin pressures remain key areas of focus.